Ligand id: 7385

Name: catumaxomab

1. Linke R, Klein A, Seimetz D. (2010)
Catumaxomab: clinical development and future directions.
MAbs, 2 (2): 129-36. [PMID:20190561]
2. Riesenberg R, Buchner A, Pohla H, Lindhofer H. (2001)
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
J. Histochem. Cytochem., 49 (7): 911-7. [PMID:11410615]
3. Ruf P, Lindhofer H. (2001)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
Blood, 98 (8): 2526-34. [PMID:11588051]
4. Sebastian M, Passlick B, Friccius-Quecke H, J├Ąger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. (2007)
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Cancer Immunol. Immunother., 56 (10): 1637-44. [PMID:17410361]
5. Shen J, Zhu Z. (2008)
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Curr. Opin. Mol. Ther., 10 (3): 273-84. [PMID:18535935]
6. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. (1999)
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.
J. Immunol., 163 (3): 1246-52. [PMID:10415020]